Mylan, U.S. finalize $465 million EpiPen settlement

BOSTON (REUTERS) – Mylan NV has finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

The U.S. Attorney’s Office in Massachusetts revealed the accord on Thursday, 10 months after Mylan said it reached a deal resolving claims it misclassified the EpiPen as a generic rather than a branded product, underpaying rebates to state Medicaid programs as a result.

“Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules,” Acting U.S. Attorney William Weinreb said in a statement.

The investigation followed a whistleblower lawsuit filed under the False Claims Act that rival drugmaker Sanofi SA (SASY.PA) filed in 2016, two years after it first raised the matter with investigators, Weinreb’s office said.

Click here to read more.

Sponsored Content